avelumab + bempegaldesleukin + talazoparib

Avelumab + bempegaldesleukin + talazoparib is an investigational **combination regimen** comprising three agents. - **Avelumab** is a human monoclonal antibody targeting programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor and enhancing antitumor immune responses. - **Bempegaldesleukin (NKTR-214)** is a pegylated interleukin-2 (IL-2) cytokine therapy designed to selectively stimulate proliferation and activation of CD8+ T-cells and natural killer (NK) cells, thus augmenting immune-mediated tumor destruction. - **Talazoparib** is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor that exploits deficiencies in DNA damage repair (notably in tumors with homologous recombination deficiencies such as BRCA mutations), leading to accumulation of DNA damage and cell death. This combination is being studied as a multi-modality immunotherapy and targeted therapy regimen in metastatic castration-resistant prostate cancer (mCRPC) patients with DNA damage repair (DDR) defects, with the aim of synergistically increasing antitumor activity by combining immune activation and synthetic lethality[1][3][7].